Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MYOK - MyoKardia Inc.

Previous close
224.91
0   0%

Share volume: 0
Last Updated: Mon 16 Nov 2020 06:00:00 AM CET
Pharmaceuticals: Other: 0%

PREVIOUS CLOSE
CHG
CHG%
$224.91
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 58%
Dept financing 3%
Liquidity 50%
Performance 16%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$224.91
P/E Ratio 
N/A
DAY RANGE
$224.91 - $224.91
EPS 
-$5.64
52 WEEK RANGE
$42.65 - $225.00
52 WEEK CHANGE
$316.42
MARKET CAP 
11.993 B
YIELD 
N/A
SHARES OUTSTANDING 
53.323 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$51,758,939
AVERAGE 10 VOLUME 
$1,310,448
AVERAGE 30 VOLUME 
$1,352,939
Company detail
CEO: Anastasios E. Gianakakos
Region: US
Website: http://www.myokardia.com
Employees: 235
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Other
Sector: Health Technology

MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.

Recent news